MedTrace Logo

Cost-effectiveness Analysis of Robot-assisted Spinal Surgery

NCT05388383 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-05-24

No results posted yet for this study

Summary

With the change of lifestyle and the aging of the population, the prevalence of Lumbar disc herniation (LDH) in my country is increasing year by year, and surgery is one of the main ways to treat LDH. Surgical robots have good application prospects in the surgical treatment of patients with lumbar degenerative diseases. Studies have shown that orthopedic robot-assisted surgery has less soft tissue damage, small surgical incisions, less bleeding, high safety, and quick postoperative recovery; it reduces the risk of spinal cord and blood vessel damage that may be caused during manual operations; does not require repeated fluoroscopy To determine the position of the nail, reduce the intraoperative radiation by more than 70%, and reduce the risk of patient infection.

The current clinical research on robotics technology mainly stays in the aspects of accuracy, effectiveness, and safety. If the technology is promoted in clinical applications, the support of health economics evaluation data is urgently needed. This study hopes to apply robot-assisted technology in LDH surgical treatment through observational research design, evaluate the therapeutic effect and treatment cost of robot-assisted surgery and conventional surgery, focus on health economics evaluation, and provide treatment options for patients and medical care in the health sector. The reasonable allocation of resources and the promotion and application of this technology provide data support.

Conditions

  • Lumbar Spine Degeneration
  • Economic Problems
  • Surgery

Interventions

DEVICE

Ti-robot

Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital

Sponsors & Collaborators

  • Beijing Jishuitan Hospital

    lead OTHER

Principal Investigators

  • tian wei, MD,PHD · Beijing Jishuitan Hospital

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-01
Primary Completion
2023-01-01
Completion
2025-01-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05388383 on ClinicalTrials.gov